24小时热门版块排行榜    

查看: 615  |  回复: 3

suibowen2010

木虫 (小有名气)


[交流] 求高人帮翻译一段说明书 急~

1 General
Responding patients may not experience an improvement in performance status on therapy and
may experience worsening. The relationship between changes in performance status, response to
therapy, and treatment-related side effects has not been established.

2 Cutaneous
Localized erythema of the extremities with edema followed by desquamation has been observed.
In case of severe skin toxicity, an adjustment in dosage is recommended [see Dose Adjustments
During Treatment (2.7)]. The discontinuation rate due to skin toxicity was 1.6% (15/965) for
metastatic breast cancer patients. Among 92 breast cancer patients premedicated with 3-day
corticosteroids, there were no cases of severe skin toxicity reported and no patient discontinued
TAXOTERE due to skin toxicity.

3 Fluid Retention
Severe fluid retention has been reported following TAXOTERE therapy [see Boxed Warning,
Premedication Regimen (2.6)]. Patients should be premedicated with oral corticosteroids prior
to each TAXOTERE administration to reduce the  incidence and severity of fluid retention [see
Premedication Regimen (2.6)]. Patients with pre-existing effusions should be closely monitored
from the first dose for the possible exacerbation of the effusions.

When fluid retention occurs, peripheral edema usually starts in the lower extremities and may
become generalized with a median weight gain of 2 kg.

Among 92 breast cancer patients premedicated  with 3-day corticosteroids, moderate fluid
retention occurred in 27.2% and severe fluid retention in 6.5%. The median cumulative dose to
onset of moderate or severe fluid retention was 819 mg/m2. 9.8% (9/92) of patients discontinued
treatment due to fluid retention: 4 patients discontinued with severe fluid retention; the
remaining 5 had mild or moderate fluid retention. The median cumulative dose to treatment
discontinuation due to fluid retention was 1021 mg/m2. Fluid retention was completely, but
sometimes slowly, reversible with a median of 16 weeks from the last infusion of TAXOTERE
to resolution (range: 0 to 42+ weeks). Patients developing peripheral edema may be treated with
standard measures, e.g., salt restriction, oral diuretic(s).

4 Neurologic
Severe neurosensory symptoms (paresthesia, dysesthesia, pain) were observed in 5.5% (53/965)
of metastatic breast cancer patients, and resulted in treatment discontinuation in 6.1%. When
these symptoms occur, dosage must be adjusted. If symptoms persist, treatment should be
discontinued  [see Dose Adjustments During Treatment (2.7)]. Patients who experienced
neurotoxicity in clinical trials and for whom follow-up information on the complete resolution of
the event was available had spontaneous reversal of symptoms with a median of 9 weeks from
onset (range: 0 to 106 weeks). Severe peripheral motor neuropathy mainly manifested as distal
extremity weakness occurred in 4.4% (42/965).


5 Asthenia
Severe asthenia has been reported in 14.9% (144/965) of metastatic breast cancer patients but has
led to treatment discontinuation in only 1.8%. Symptoms of fatigue and weakness may last a few
days up to several weeks and may be associated with deterioration of  performance status in
patients with progressive disease.

6. ADVERSE  REACTIONS
Adverse reactions are described for TAXOTERE according to indication.

6.1  Clinical Trial Experience

• Breast Cancer

Monotherapy with TAXOTERE for locally advanced or metastatic breast cancer after
failure of prior chemotherapy
TAXOTERE 100 mg/m2: Adverse drug reactions occurring in at least 5% of patients are
compared for three populations who received TAXOTERE administered at 100 mg/m2
as a 1-hour infusion every 3 weeks: 2045 patients with various tumor types and normal baseline liver function tests; the subset of 965 patients with locally advanced or metastatic breast cancer, both previously treated and untreated with chemotherapy, who had normal baseline liver function
tests; and an additional 61 patients with various tumor types who had abnormal liver function
tests at baseline. These reactions were described using COSTART terms and were considered
possibly or probably related to TAXOTERE. At least 95% of these patients did not receive
hematopoietic support. The safety profile is generally similar in patients receiving TAXOTERE
for the treatment of breast cancer and in patients with other tumor types (See Table 4).

» 猜你喜欢

» 抢金币啦!回帖就可以得到:

查看全部散金贴

已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

ljason

新虫 (文学泰斗)


suibowen2010(金币+1, 翻译EPI+1): 额~确实是都翻译 不过我已经翻译完了 呵呵 2011-04-06 20:58:54
Mally89(翻译EPI-1): 无效应助!~收回EPI,多谢理解合作!~欢迎常来翻译求助版!~好运!~ 2011-04-07 09:41:23
lz要翻译哪一部分,不会都翻译吧
3楼2011-04-06 14:46:32
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

hulinzhou

金虫 (正式写手)


suibowen2010(金币+1): 确实是挺长的啊 不过我已经翻译完了! 2011-04-06 20:59:25
这么长
4楼2011-04-06 15:01:20
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
简单回复
Mally892楼
2011-04-01 16:57   回复  
suibowen2010(金币+1, 翻译EPI+1): 嘿嘿 没有办法啊 任务...看的不是很到位 很多话不知道怎么说 所以才来这求助高人啊~ 2011-04-01 19:48:04
ringzhu(翻译EPI-1): 无效应助 2011-04-06 12:41:16
哇!
相关版块跳转 我要订阅楼主 suibowen2010 的主题更新
普通表情 高级回复 (可上传附件)
最具人气热帖推荐 [查看全部] 作者 回/看 最后发表
[基金申请] 欢迎发来filecode的Mz6后的代码验证其规律 +31 医学老男孩 2026-08-13 69/3450 2026-08-16 00:16 by mo_mo_mo_mo
[基金申请] 有时候,自然基金真的不能太认真 (我的申报经验) +9 majunge000 2026-08-11 11/550 2026-08-15 23:20 by botar
[基金申请] 时间戳又变了8-15 +12 archvillain 2026-08-15 23/1150 2026-08-15 20:47 by foyo404
[基金申请] filecode +8 cratir 2026-08-14 12/600 2026-08-15 18:08 by zyfgau
[基金申请] 小木虫上这么多卖论文的,真有人买论文么?感觉没必要啊 +12 Tide man 2026-08-10 13/650 2026-08-15 16:34 by 氺木
[基金申请] 关于Filecode分析方法 +10 majunge000 2026-08-10 13/650 2026-08-15 12:26 by hanpeng972
[基金申请] 各位道友,我要去昆明玩几天,回来见。 +7 Tide man 2026-08-14 8/400 2026-08-15 01:11 by arzu_hma
[基金申请] 咱们一起用铁证分析2026国家社科基金中标与否 +7 启萌科技 2026-08-12 22/1100 2026-08-14 23:45 by Noways
[基金申请] 是这周出结果还是下周出结果? +4 yuleib84 2026-08-11 4/200 2026-08-14 23:05 by lfy8008
[硕博家园] 请教兼职经验 +3 是阿文鸭 2026-08-09 3/150 2026-08-14 12:07 by HER12025
[基金申请] filecode +15 documentary 2026-08-10 17/850 2026-08-14 10:08 by kissu88
[基金申请] FileCode能看出啥? +10 要乐观耀哥 2026-08-10 32/1600 2026-08-14 09:37 by 要乐观耀哥
[文学芳草园] 阿姨 +4 汪汪锅 2026-08-09 4/200 2026-08-13 19:43 by arzu_hma
[基金申请] 静等基金结果 +8 gjjjzhong 2026-08-10 21/1050 2026-08-13 17:56 by 且听虎啸
[基金申请] 重要来源:本周末出结果 +10 瞬息宇宙 2026-08-12 10/500 2026-08-13 15:46 by likettle
[基金申请] 综述论文作为代表作会不会影响评审专家的印象分? +11 yufeiwaner 2026-08-09 13/650 2026-08-12 08:17 by yufeiwaner
[基金申请] 什么时候出结果,有咨询渠道??? +3 Tide man 2026-08-11 3/150 2026-08-11 17:54 by kudofaye
[基金申请] 确定了,国自然21号放榜 +6 布布和一二 2026-08-10 7/350 2026-08-10 19:15 by 2000zf36392
[基金申请] 据悉今年马上要出结果了 +7 瞬息宇宙 2026-08-10 8/400 2026-08-10 12:42 by Vivilian
[基金申请] 面上项目filecode邪修 +5 西山十月 2026-08-09 7/350 2026-08-10 07:32 by 仁砚薪传
信息提示
请填处理意见